Millennium Management’s Iovance Biotherapeutics IOVA Stock Holding History

Millennium Management’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-235,500	Closed	-$643K	–	6026
2025 Q4	$643K	Buy	+235,500	New	+$545K	﹤0.01%	4783
2025 Q2	–	Sell	-100,000	Closed	-$333K	–	6092
2025 Q1	$333K	Buy	+100,000	New	+$516K	﹤0.01%	5042
2024 Q3	–	Sell	-50,000	Closed	-$401K	–	6281
2024 Q2	$401K	Buy	+50,000	New	+$536K	﹤0.01%	4736
2024 Q1	–	Sell	-51,900	Closed	-$422K	–	6409
2023 Q4	$422K	Sell	51,900 -1,800	-3%	-$9.42K	﹤0.01%	4744
2023 Q3	$244K	Buy	+53,700	New	+$351K	﹤0.01%	5024
2022 Q3	–	Sell	-321,800	Closed	-$3.55M	–	7262
2022 Q2	$3.55M	Buy	321,800 +213,700	+198%	+$2.8M	﹤0.01%	3136
2022 Q1	$1.8M	Buy	+108,100	New	+$1.67M	﹤0.01%	3988
2021 Q3	–	Sell	-20,000	Closed	-$520K	–	7008
2021 Q2	$520K	Sell	20,000 -120,000	-86%	-$3.12M	﹤0.01%	5270
2021 Q1	$4.43M	Buy	140,000 +50,000	+56%	+$2.07M	﹤0.01%	2711
2020 Q4	$4.18M	Sell	90,000 -20,000	-18%	-$794K	﹤0.01%	2621
2020 Q3	$3.62K	Buy	+110,000	New	+$3.37M	﹤0.01%	2107
2020 Q1	–	Sell	-184,400	Closed	-$5.1M	–	4164
2019 Q4	$5.1M	Buy	+184,400	New	+$4.19M	0.01%	1917
2019 Q3	–	Sell	-139,500	Closed	-$3.42M	–	4358
2019 Q2	$3.42M	Buy	+139,500	New	+$2.1M	0.01%	2071

Other funds holding IOVA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MFM

MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ICM

Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Millennium Management's IOVA Position: Q1 2026 in Review

Millennium Management increased its Iovance Biotherapeutics (IOVA) stake by 43% in Q1 2026, buying an estimated $9.05M and bringing the position to 9,414,292 shares worth $33M. The position accounts for 0.01% of the portfolio, ranked #1147.

Millennium Management first reported a position in IOVA in Q1 2015 and has held it in 38 quarters since. The position peaked at $39.5M in Q1 2022. 285 funds tracked by Wall St. Rank hold IOVA as of Q1 2026.

Millennium Management held 9,414,292 shares of Iovance Biotherapeutics worth $33M as of Q1 2026.
Millennium Management bought 2,828,760 Iovance Biotherapeutics shares in Q1 2026, an estimated $9.05M.
Iovance Biotherapeutics made up 0.01% of Millennium Management's portfolio in Q1 2026, its #1147 holding.
Millennium Management first reported a position in Iovance Biotherapeutics in Q1 2015 and has held it in 38 quarters since.
Millennium Management's Iovance Biotherapeutics position peaked at $39.5M in Q1 2022.
285 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.